+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Idiopathic Pulmonary Fibrosis Market by Drug Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • ID: 5561181
  • Report
  • January 2022
  • Region: Global
  • 169 Pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • AstraZeneca Plc
  • Biogen
  • Biogen Inc.
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • FibroGen, Inc.
The global idiopathic pulmonary fibrosis market was valued at $3,126.08 million in 2020, and is projected to reach $6,169.37 million by 2030, registering a CAGR of 7.0% from 2021 to 2030.



Idiopathic pulmonary fibrosis is a chronic lung disease or a condition in which the tissues in lungs become thick and stiff over time. As a result of thickening of lung tissues, brain, and other organs are unable receive optimum oxygen. This condition causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen into the bloodstream effectively. The disease usually affects people between the ages of 50 and 70. Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung diseases (also known as ILD), which describes lung diseases that involve inflammation or scarring in the lung.

The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough. Many affected individuals also experience a loss of appetite and gradual weight loss. Some people with idiopathic pulmonary fibrosis develop widened and rounded tips of the fingers and toes (clubbing) resulting from a shortage of oxygen.

The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.

The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug, distribution channel and region. According to type of drug, the market is divided into pirfenidone and nintedanib. On the basis of distribution channel, the market is divided into hospital pharmacies, retail pharmacies and online providers. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA)

The major companies profiled in the report include AstraZeneca Plc, Biogen Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Mission Therapeutics., GNI Group Ltd, Galapagos NV, Biogen, Bristol-Myers Squibb Company., and Shiongi Co Ltd.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global idiopathic pulmonary fibrosis market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the products and end users of idiopathic pulmonary fibrosis used across the globe.
  • Key market players and their strategies have been analysed to understand the competitive outlook of the market.

By Drug Type

  • Pirfenidone
  • Nintedani

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Provider

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Players

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim
  • GNI Group Ltd
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
  • Shiongi co Ltd
  • Mission Therapeutics
  • Biogen, Inc
  • Galapagos NV
  • FibroGen, Inc
Frequently Asked Questions about the Global Idiopathic Pulmonary Fibrosis Market

What is the estimated value of the Global Idiopathic Pulmonary Fibrosis Market?

The Global Idiopathic Pulmonary Fibrosis Market was estimated to be valued at $3126.1 million in 2020.

What is the growth rate of the Global Idiopathic Pulmonary Fibrosis Market?

The growth rate of the Global Idiopathic Pulmonary Fibrosis Market is 7.0%, with an estimated value of $6169.4 million by 2030.

What is the forecasted size of the Global Idiopathic Pulmonary Fibrosis Market?

The Global Idiopathic Pulmonary Fibrosis Market is estimated to be worth $6169.4 million by 2030.

Who are the key companies in the Global Idiopathic Pulmonary Fibrosis Market?

Key companies in the Global Idiopathic Pulmonary Fibrosis Market include AstraZeneca Plc, Biogen Inc., Boehringer Ingelheim, F. Hoffmann, La Roche, FibroGen, Inc., Mission Therapeutics., GNI Group Ltd and Biogen.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc
  • Biogen
  • Biogen Inc.
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • FibroGen, Inc.

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2020
3.4. Porter’s five forces analysis
3.4.1. Bargaining power of suppliers
3.4.2. Bargaining power of buyers
3.4.3. Threat of new entrants
3.4.4. Threat of substitutes
3.4.5. Intensity of competitive rivalry
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.1.1. Increase in incidences of cancer across the globe
3.5.1.2. Surge in global geriatric population
3.5.1.3. Increase in cigarette smoking
3.5.2. Restraint
3.5.2.1. Lack of awareness & Proper treatment.
3.5.3. Opportunities
3.5.3.1. Increase in number of pipeline drugs
3.5.3.2. Growth opportunities in emerging markets
3.5.4. Impact analyses
3.6. COVID-19 impact analysis on market
3.7. Pipeline analyses
CHAPTER 4: IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Pirfenidone
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Nintedanib
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
CHAPTER 5: IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast, by distribution channel
5.2. Hospital- pharmacies
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Retail pharmacy
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Online Pharmacy
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.3. North America market size and forecast, by drug type
6.2.4. North America market size and forecast, by distribution channel
6.2.4.1. U.S.
6.2.4.2. U.S. market size and forecast, by drug type
6.2.4.3. U.S. market size and forecast, by distribution channel
6.2.4.4. Canada
6.2.4.5. Canada market size and forecast, by drug type
6.2.4.6. Canada market size and forecast, by distribution channel
6.2.4.7. Mexico
6.2.4.8. Mexico market size and forecast, by drug type
6.2.4.9. Mexico market size and forecast, by distribution channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe market size and forecast, by country
6.3.3. Europe market size and forecast, by drug type
6.3.4. Europe market size and forecast, by distribution channel
6.3.4.1. Germany.
6.3.4.2. Germany market size and forecast, by drug type
6.3.4.3. Germany market size and forecast, by distribution channel
6.3.4.4. France
6.3.4.5. France market size and forecast, by drug type
6.3.4.6. France market size and forecast, by distribution channel
6.3.4.7. UK
6.3.4.8. UK market size and forecast, by drug type
6.3.4.9. UK market size and forecast, by distribution channel
6.3.4.10. Italy
6.3.4.11. Italy market size and forecast, by drug type
6.3.4.12. Italy market size and forecast, by distribution channel
6.3.4.13. Spain
6.3.4.14. Spain market size and forecast, by drug type
6.3.4.15. Spain market size and forecast, by distribution channel
6.3.4.16. Rest of Europe
6.3.4.17. Rest of Europe market size and forecast, by drug type
6.3.4.18. Rest of Europe market size and forecast, by distribution channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.3. Asia-Pacific market size and forecast, by drug type
6.4.4. Asia-Pacific market size and forecast, by distribution channel
6.4.4.1. Japan
6.4.4.2. Japan market size and forecast, by drug type
6.4.4.3. Japan market size and forecast, by distribution channel
6.4.4.4. China
6.4.4.5. China market size and forecast, by drug type
6.4.4.6. China market size and forecast, by distribution channel
6.4.4.7. India
6.4.4.8. India market size and forecast, by drug type
6.4.4.9. India market size and forecast, by distribution channel
6.4.4.10. Australia
6.4.4.11. Australia market size and forecast, by drug type
6.4.4.12. Australia market size and forecast, by distribution channel
6.4.4.13. South Korea
6.4.4.14. South Korea market size and forecast, by drug type
6.4.4.15. South Korea market size and forecast, by distribution channel
6.4.4.16. Rest of Asia-Pacific
6.4.4.17. Rest of Asia-Pacific market size and forecast, by drug type
6.4.4.18. Rest of Asia-Pacific market size and forecast, by distribution channel
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.3. LAMEA market size and forecast, by drug type
6.5.4. LAMEA market size and forecast, by application
6.5.4.1. Brazil
6.5.4.2. Brazil market size and forecast, by drug type
6.5.4.3. Brazil market size and forecast, by distribution channel
6.5.4.4. Saudi Arabia
6.5.4.5. Saudi Arabia market size and forecast, by drug type
6.5.4.6. Saudi Arabia market size and forecast, by distribution channel
6.5.4.7. South Africa
6.5.4.8. South Africa market size and forecast, by drug type
6.5.4.9. South Africa market size and forecast, by distribution channel
6.5.4.10. Rest of LAMEA
6.5.4.11. Rest of LAMEA market size and forecast, by drug type
6.5.4.12. Rest of LAMEA market size and forecast, by distribution channel
CHAPTER 7: COMPANY PROFILES
7.1. AstraZeneca Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. Bristol-Myers Squibb Company
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Biogen,Inc
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. FibroGen, Inc
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. F. Hoffmann-La Roche AG
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. GNI Group Ltd.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Galapagos NV.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. Mission Therapeutics
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.10. Shionogi & Co Ltd
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
List of Tables
TABLE 01. PRODUCT PIPELINE ANALYSIS (PHASE II & III)
TABLE 02. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 03. PIRFENIDONE MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 04. NINTEDANIB MARKET, BY REGION, 2020–2030($MILLION)
TABLE 05. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 06. HOSPITAL- PHARMACIES MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 07. IDIOPATHIC PULMONARY FIBROSIS MARKET FOR RETAIL PHARMACIES, BY REGION, 2020–2030 ($MILLION)
TABLE 08. IDIOPATHIC PULMONARY FIBROSIS MARKETFOR ONLINE PHARMACY, BY REGION, 2020–2030 ($MILLION)
TABLE 09. IDIOPATHIC PULMONARY FIBROSIS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)
TABLE 10. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 11. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 12. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 13. U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 14. U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 15. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 16. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 17. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 18. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 19. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 20. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 21. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 22. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 23. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 24. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 25. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 26. UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 27. UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 28. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 29. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 30. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 31. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 32. REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 33. REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 34. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 35. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 36. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 37. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 38. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 39. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 40. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 41. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 42. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 43. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 44. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 45. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 46. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 47. REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 49. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 50. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 51. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 52. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 53. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 54. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 55. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 56. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 57. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 58. REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 59. REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 60. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 61. ASTRAZENECA: OPERATING SEGMENTS
TABLE 62. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 63. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 64. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 65. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 66. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 67. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 68. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 69. BIOGEN: COMPANY SNAPSHOT
TABLE 70. BIOGEN: OPERATING SEGMENTS
TABLE 71. BIOGEN: PRODUCT PORTFOLIO
TABLE 72. FIBROGEN: COMPANY SNAPSHOT
TABLE 73. FIBROGEN: OPERATING SEGMENTS
TABLE 74. LILLY: PRODUCT PORTFOLIO
TABLE 75. ROCHE: COMPANY SNAPSHOT
TABLE 76. ROCHE: OPERATING SEGMENTS
TABLE 77. ROCHE: PRODUCT PORTFOLIO
TABLE 78. GNI: COMPANY SNAPSHOT
TABLE 79. GNI: PRODUCT SEGMENTS
TABLE 80. GNI: PRODUCT PORTFOLIO
TABLE 81. GALAPAGOS: COMPANY SNAPSHOT
TABLE 82. GALAPAGOS: OPERATING SEGMENTS
TABLE 83. GALAPAGOS: PRODUCT PORTFOLIO
TABLE 84. MISSION: COMPANY SNAPSHOT
TABLE 85. MISSION: OPERATING SEGMENTS
TABLE 86. MISSION: PRODUCT PORTFOLIO
TABLE 87. SHIONOGI: COMPANY SNAPSHOT
TABLE 88. SHIONOGI: OPERATING SEGMENTS
TABLE 89. SHIONOGI: PRODUCT TYPE PORTFOLIO
List of Figures
FIGURE 01. IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP PLAYER POSITIONING, 2020
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. HIGH BARGAINING POWER OF BUYERS
FIGURE 06. HIGH THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. MODERATR INTENSITY OF COMPETITIVE RIVALRY
FIGURE 09. IMPACT ANALYSES
FIGURE 10. COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKETFOR PIRFENIDONE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 11. COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKET FOR NINTEDANIB, BY COUNTRY, 2020 & 2030 (%)
FIGURE 12. COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKETFOR HOSPITAL- PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 13. COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14. COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKETFOR ONLINE PROVIDER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. ASTRAZENECA: REVENUE, 2018–2020($MILLION)
FIGURE 16. ASTRAZENECA: REVENU.S.ARE, BY SEGMENT, 2020(%)
FIGURE 17. ASTRAZENECA: REVENU.S.ARE, BY REGION, 2020(%)
FIGURE 18. BOEHRINGER INGELHEIM: NET SALES, 2018–2020 ($MILLION)
FIGURE 19. BOEHRINGER INGELHEIM: REVENU.S.ARE, BY SEGMENTS, 2020 (%)
FIGURE 20. BOEHRINGER INGELHEIM: REVENU.S.ARE, BY REGION, 2020 (%)
FIGURE 21. REVENUE, 2018–2020 ($MILLION)
FIGURE 22. BRISTOL-MYERS SQUIBB: REVENU.S.ARE, BY REGION, 2020 (%)
FIGURE 23. BIOGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 24. BIOGEN: REVENU.S.ARE BY REGION, 2020(%)
FIGURE 25. FIBROGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 26. FIBROGEN: REVENU.S.ARE, BY REGION, 2020(%)
FIGURE 27. ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 28. ROCHE: REVENU.S.ARE, BY SEGMENT, 2020 (%)
FIGURE 29. ROCHE: REVENU.S.ARE, BY REGION, 2020(%)
FIGURE 30. GNI: NET SALES, 2018–2020 ($MILLION)
FIGURE 31. GALAPAGOS: NET SALES, 2018–2020 ($MILLION)
FIGURE 32. SHIONOGI: REVENUE, 2018–2020 ($MILLION)
Note: Product cover images may vary from those shown
  • AstraZeneca Plc
  • Biogen Inc.
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • FibroGen, Inc.
  • Mission Therapeutics.
  • GNI Group Ltd
  • Galapagos NV
  • Biogen
  • Bristol-Myers Squibb Company.
  • Shiongi Co Ltd
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...